Back to top
more

NeoGenomics (NEO)

(Delayed Data from NSDQ)

$17.17 USD

17.17
746,651

-0.33 (-1.89%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $17.19 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NEO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for NeoGenomics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 415 438 515 296 173
Receivables 131 120 112 107 94
Notes Receivable 0 0 0 0 0
Inventories 24 24 23 30 14
Other Current Assets 26 23 31 16 9
Total Current Assets 597 605 682 449 291
Net Property & Equipment 92 103 109 86 64
Investments & Advances 0 0 0 30 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 896 931 969 332 325
Deposits & Other Assets 5 5 7 47 3
Total Assets 1,681 1,740 1,870 988 710
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 20 21 18 25 20
Current Portion Long-Term Debt 0 0 0 0 5
Current Portion Capital Leases 0 0 1 3 5
Accrued Expenses 68 55 56 36 29
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 8 5 4 2
Total Current Liabilities 96 90 87 73 64
Mortgages 0 0 0 0 0
Deferred Taxes/Income 24 35 55 5 16
Convertible Debt 538 535 532 168 0
Long-Term Debt 0 0 0 0 92
Non-Current Capital Leases 0 0 0 1 3
Other Non-Current Liabilities 13 13 14 4 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 740 742 762 294 202
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,190 1,161 1,124 701 520
Retained Earnings -247 -159 -15 -7 -11
Other Equity -2 -4 -1 0 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 942 998 1,108 694 507
Total Liabilities & Shareholder's Equity 1,681 1,740 1,870 988 710
Total Common Equity 942 998 1,108 694 507
Shares Outstanding 127.47 126.30 123.10 111.00 104.40
Book Value Per Share 7.39 7.90 9.00 6.25 4.86

Fiscal Year End for NeoGenomics, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 388 385 415 402 409
Receivables 147 140 131 133 125
Notes Receivable NA 0 0 0 0
Inventories 23 20 24 24 25
Other Current Assets 27 28 26 28 25
Total Current Assets 584 574 597 587 585
Net Property & Equipment 92 88 92 95 100
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles 879 888 896 905 913
Deposits & Other Assets 4 4 5 5 5
Total Assets 1,643 1,640 1,681 1,678 1,695
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable 86 18 20 17 18
Current Portion Long-Term Debt 200 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 53 68 66 64
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 2 4 6
Total Current Liabilities 290 77 96 93 95
Mortgages NA 0 0 0 0
Deferred Taxes/Income 23 23 24 25 29
Convertible Debt 340 539 538 537 537
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 12 13 13 13
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 727 717 740 731 739
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,199 1,190 1,182 1,173
Retained Earnings NA -274 -247 -233 -214
Other Equity NA -1 -2 -2 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 916 923 942 947 956
Total Liabilities & Shareholder's Equity 1,643 1,640 1,681 1,678 1,695
Total Common Equity 100,915 923 942 947 956
Shares Outstanding 127.71 127.71 127.40 127.50 127.50
Book Value Per Share 790.19 7.23 7.39 7.43 7.50